BioCurex Announces New Blood Test For Cancer Detection with 95% Sensitivity, 95% Specificity -- Addressing a $2 Billion Dollar Market.
RANCHO SANTA MARGARITA Santa Margarita ("Saint Margaret") may refer to:
BioCurex Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :BOCX) announces initial results for its Serum-RECAF(TM) cancer test. A universal cancer marker can be used not only for diagnosis and follow up, but also for screening. The potential market for Serum-RECAF(TM) is estimated in $2B per year.
The Company has recently been granted a patent by the US Patent Office -- No. US6,514,685 B1. This patent and others pending or granted in another 22 countries encompass the technology used in the blood test announced herein.
BioCurex has also been granted FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. clearance for its Histo-RECAF(TM) kit for cancer diagnosis on tissue sections and biopsies.
Dr. Moro stated: "This is what we live for. Even though these results are preliminary, the numbers are impressive. Now we have to test more samples and other types of cancer before we can draw final conclusions. Also, the chemistry of the assay needs to be improved before it can be released commercially.
"One thing is clear. These results strongly suggest that using RECAF we can tell if a person has cancer, probably of any type and with a high degree of accuracy, using just a drop of blood. The possibilities are exciting. For example, we could screen people who go for a routine checkup check·up
1. An examination or inspection.
2. A general physical examination.
checkup See Yearly checkup. , in a similar manner to what is now done for prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , with the advantage that we could be detecting all different types of malignancies. Or we could use the test for follow-up. If a patient was operated for cancer and he or she was RECAF positive, then subsequent periodic tests could be used to spot a recurrence or a metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases
1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to even before symptoms appear. Besides the obvious medical advantages, from a market point of view, this means that the number of tests could supersede To obliterate, replace, make void, or useless.
Supersede means to take the place of, as by reason of superior worth or right. A recently enacted statute that repeals an older law is said to supersede the prior legislation. the number of cancer patients by far. I am also happy to announce that we are advancing according to according to
1. As stated or indicated by; on the authority of: according to historians.
2. In keeping with: according to instructions.
3. plan in creating a whole line of original products for cancer diagnosis."
The study shows that overall, 95 out of 100 cancer patients are positive with the test, while false positives are below the accepted 5% standard. The sensitivity of a test is the percentage of cancers it detects out of 100 cancer patients. For example, 95% sensitivity means that the test will pick up 95 out of 100 patients with cancer. Specificity is the percentage of normal individuals that appear as negative: 96% specificity indicates that 4 out of 100 normal people will test positive for cancer. In Medicine, 5% false positives (95% specificity) is the accepted standard.
The study included 147 normal samples and 91 cancer samples distributed as follows: 22 breast cancers, 31 stomach cancers and 38 miscellaneous types of cancer including cervix cervix /cer·vix/ (ser´viks) pl. cer´vices [L.]
2. the front portion of the neck.
3. cervix uteri. , lung, head and neck, ovarian ovarian /ovar·i·an/ (o-var´e-an) pertaining to an ovary or ovaries.
pertaining to an ovary.
ovarian agenesis , colon and rectal cancers Rectal Cancer Definition
The rectum is the portion of the large bowel that lies in the pelvis, terminating at the anus. Cancer of the rectum is the disease characterized by the development of malignant cells in the lining or epithelium of the rectum. .
The sensitivity of the test ranged from 84% for stomach cancers to 100% for breast cancers (hence the 95% overall sensitivity in the study).
By comparison, current markers developed for other cancers detect only 35%-50% of cases when used in breast cancer.
Stomach cancers showed 84% detection with Serum-RECAF(TM), a value unattainable by any other current blood test such as CA 19-9(TM), which detects 56% of stomach cancers with only 75% specificity and CA 72-4 (TM) which has a 51% sensitivity with 97% specificity. (Ref: Am. J. Surgery: 181,16-19, 2001)
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is practically absent in most normal or benign cells. Detailed information about BioCurex may be obtained from its Web site.
In some cases, percentages in the reported study have been extrapolated from less than 100 cases.
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.